使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, everyone, and welcome to today's DexCom third quarter results conference call. Today's call is being recorded. (OPERATOR INSTRUCTIONS.)
各位大家好,歡迎參加今天的 DexCom 第三季財報電話會議。今天的會議將被錄音。(接線員指示。)
At this time, for opening remarks and introductions, I'd like to turn the call over to Mr. Terry Gregg, President and CEO. Please go ahead, sir.
此刻,為了開場致詞與介紹,我想把電話交給總裁兼執行長 Terry Gregg 先生。先生,請開始。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Thank you, and thank you for joining us this afternoon for the DexCom third quarter call. Before we get into the formal presentation, I would like Steve Pacelli, our Senior Vice President of Corporate Affairs to begin. Steve?
謝謝,也感謝各位今天下午加入 DexCom 第三季電話會議。在進入正式簡報之前,我想請我們的企業事務資深副總裁 Steve Pacelli 先開始。Steve?
Steve Pacelli - SVP Corporate Affairs
Steve Pacelli - SVP Corporate Affairs
Thanks, Terry. Just a brief Safe Harbor Statement. Some of the statements that we will make in today's call may constitute forward-looking statements. These statements reflect Management's expectations about future events, operating plans, and performance, and speak only as of the date hereof. These forward-looking statements involve a number of risks and uncertainties. A list of the factors that could cause actual results to be materially expressed or implied by any of these forward-looking statements is detailed under risk factors and elsewhere in our Annual Report on Form 10-K, our quarterly reports on Form 10-Q, and our other reports filed with the SEC. We undertake no obligation to update publicly or revise these forward-looking statements for any reason.
謝謝你,Terry。先做一段簡短的安全港聲明。我們在今天電話會議中所做的部分陳述,可能構成前瞻性陳述。這些陳述反映管理階層對未來事件、營運計畫與績效的預期,且僅以本日為準。這些前瞻性陳述涉及多項風險與不確定性。可能導致實際結果與任何前瞻性陳述所明示或暗示者出現重大差異的因素清單,已在我們的 Form 10-K 年度報告、Form 10-Q 季度報告,以及其他向美國證券交易委員會(SEC)提交的報告中的風險因素與其他章節詳述。我們不承擔因任何原因公開更新或修訂這些前瞻性陳述的義務。
Terry?
Terry?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Thanks, Steve. We'll give just kind of a brief rundown on the agenda. We're going to start off with a financial review by Jess Roper, and give you an update on our current situation with regards to the fires that the community has experienced, and then get into the Seven launch and update about the rest of the business, follow-up with a Q&A period.
謝謝你,Steve。我們先簡要說明一下議程。我們將先由 Jess Roper 進行財務回顧,並就社區近期經歷的火災對我們目前狀況的影響提供最新資訊,接著談 Seven 的上市進展以及其他業務更新,最後進入問答環節。
So on the financial review, Jess Roper, our Interim CFO.
接下來進行財務回顧,由我們的代理財務長 Jess Roper。
Jess Roper - Interim CFO
Jess Roper - Interim CFO
Thank you, Terry. Welcome, everyone.
謝謝你,Terry。各位好,歡迎大家。
For the third quarter of 2007 DexCom's revenues grew to $1.2 million, an increase of over 45% from the $841,000 in revenues reported for the third quarter of 2006, and an increase of more than 41% from the $863,000 in revenues reported for the second quarter of 2007.
2007 年第三季,DexCom 的營收成長至 120 萬美元,較 2006 年第三季所報告的 84.1 萬美元營收增加逾 45%,亦較 2007 年第二季所報告的 86.3 萬美元營收增加逾 41%。
We added 683 new customers during the third quarter and had approximately 745 customers that upgraded from their STS three-day system to our recently approved second generation Seven System. As you may recall, we announced an upgrade program in late Q2 allowing our STS three-day customers to upgrade to the Seven System. Since the revenues for the quarter were up over 75% compared to the third quarter of 2006 and up over 36% compared to the second quarter of 2007.
我們在第三季新增 683 位新客戶,並約有 745 位客戶從其 STS 三日系統升級至我們近期獲准的第二代 Seven 系統。如各位所記得,我們在第二季末宣布一項升級方案,讓 STS 三日系統客戶可升級至 Seven 系統。由於此方案,本季營收較 2006 年第三季成長逾 75%,較 2007 年第二季成長逾 36%。
Cost of sales decreased to $3.1 million for the third quarter of 2007 compared to $3.4 million for the third quarter of 2006. The decline in cost of sales was primarily related to the decrease in direct product costs and better labor utilization. We continue to realize improvements on our manufacturing capabilities and production yields since our initial launch in 2006.
2007 年第三季銷貨成本降至 310 萬美元,低於 2006 年第三季的 340 萬美元。銷貨成本下降主要與直接產品成本降低及勞動力運用效率提升有關。自 2006 年初次上市以來,我們持續在製造能力與生產良率方面實現改善。
Research and development expense declined by approximately $1 million to $3.7 million for the third quarter of 2007 compared to $4.6 million for the third quarter of 2006. Changes in R&D expense includes $713,000 in lower development costs and $448,000 lower clinical and regulatory costs that were partially offset by higher quality assurance costs. R&D expense for Q3 of 2007 was down sequentially from Q2 by $357,000 due primarily to lower clinical and regulatory costs.
2007 年第三季研發費用較 2006 年第三季的 460 萬美元下降約 100 萬美元至 370 萬美元。研發費用的變動包括開發成本減少 71.3 萬美元,以及臨床與法規成本減少 44.8 萬美元,部分被較高的品質保證成本所抵銷。2007 年第三季研發費用較第二季按季減少 35.7 萬美元,主要因臨床與法規成本降低。
Our selling, general, and administrative expense decreased by approximately $1.1 million to $5.9 million for the third quarter of 2007 compared to $7.1 million for the same quarter in 2006. The decrease was primarily due to $1.1 million in lower marketing costs, major elements in decreased SG&A expense include $869,000 in lower trade show costs and $434,000 in sales samples, offset by $609,000 in increased personnel related costs. SG&A expense for Q3 of 2007 was up sequentially from Q2 by $474,000 due primarily to additional trade show costs.
我們的銷售、一般及行政費用在 2007 年第三季較 2006 年同期的 710 萬美元下降約 110 萬美元至 590 萬美元。下降主要由於行銷成本減少 110 萬美元;SG&A 費用下降的主要項目包括展會成本減少 86.9 萬美元及銷售樣品減少 43.4 萬美元,但被人員相關成本增加 60.9 萬美元所抵銷。2007 年第三季 SG&A 費用較第二季按季增加 47.4 萬美元,主要因額外的展會成本。
Net interest income declined by approximately $700,000 to $119,000 for the third quarter of 2007 compared to $818,000 for the third quarter of 2006. The decrease was due to an $866,000 increase in interest expense primarily related to our $60 million in convertible notes, which was partially offset by higher interest income for the period.
2007 年第三季淨利息收入較 2006 年第三季的 81.8 萬美元下降約 70 萬美元至 11.9 萬美元。下降原因為利息費用增加 86.6 萬美元,主要與我們 6,000 萬美元的可轉換公司債相關;部分被本期較高的利息收入所抵銷。
We reported a net loss of $11.4 million or $0.40 per share for the third quarter of 2007, down from $13.4 million or $0.48 per share for the third quarter of 2006. The approximate $2 million in lower reported net loss from the prior year was primarily the result of reduced operating costs and increased revenues, offset by lower net interest income.
我們在 2007 年第三季報告淨損 1,140 萬美元(每股 0.40 美元),低於 2006 年第三季的淨損 1,340 萬美元(每股 0.48 美元)。相較前一年淨損約減少 200 萬美元,主要是營運成本降低與營收增加所致,但部分被淨利息收入下降所抵銷。
We ended the quarter with a strong balance sheet. At September 30th, 2007 we had $74 million in cash and marketable securities and working capital of $71 million. We continue to focus on controlling our expenses and cash usage. Net cash used in operating activities decreased to $7.8 million [to] $26 million for the nine months ending September 30th, 2007, compared to $33.8 million net cash used for the same period in 2006. The decreased use in cash used in operations was primarily due to less cash invested in inventories, less cash used to pay-down payables and accrued liabilities, and in lower net loss compared to the same nine-month period in 2006.
本季結束時,我們的資產負債表依然強勁。截至 2007 年 9 月 30 日,我們持有 7,400 萬美元的現金及有價證券,營運資金為 7,100 萬美元。我們持續專注於控制費用與現金使用。2007 年截至 9 月 30 日止九個月,營運活動使用的淨現金降至 780 萬美元 [to] 2,600 萬美元,相較 2006 年同期為 3,380 萬美元。營運用現金減少主要因投入存貨的現金較少、用於償付應付帳款及應計負債的現金較少,以及相較 2006 年同一九個月期間淨損較低。
As we've previously reported, in March 2007 we purchased four separate call spread options in conjunction with the issuance of $60 million in convertible senior notes. In September of 2007 and as settlement for the first of our four call spread options we received approximately 154,000 shares of our own stock valued at $1.4 million on the date of settlement. Based on specific cap prices limits the maximum additional value we could receive for the remaining three call spread options through March 2009 is approximately $40 million.
如我們先前所報告,於 2007 年 3 月,我們在發行 6,000 萬美元可轉換優先票據的同時,購買了四筆獨立的買權價差(call spread)選擇權。2007 年 9 月,作為四筆買權價差選擇權中第一筆的結算,我們收到約 154,000 股本公司股票,於結算日估值為 140 萬美元。依特定上限價格限制,截至 2009 年 3 月,我們就其餘三筆買權價差選擇權可能取得的最大額外價值約為 4,000 萬美元。
I will now turn it back to our CEO, Terry.
接下來我把電話交回給我們的執行長 Terry。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Thanks, Jess.
謝謝你,Jess。
I'd first like to start off with a brief update on the wildfires, which recently plagued San Diego County. We did not experience any structural damage as a result of the fires. We voluntarily elected to close our operations on Monday and Tuesday of last week to enable our employees to attend to their families and their homes. We resumed operations on a limited basis on Wednesday, and by Thursday we were fully operational again.
我想先就近期困擾聖地牙哥郡的野火做一個簡短更新。我們並未因火災而遭受任何建築結構損害。上週一與週二,我們自願選擇暫停營運,讓員工能照顧家人與住家。我們於週三以有限度方式恢復營運,並在週四全面恢復正常運作。
We have also confirmed that our key suppliers, located in San Diego, are fully operational. During the crisis we continued to provide uninterrupted technical and customer support for our patients. Although manufacturing was limited for several days we currently have sufficient sensor inventory to meet patient demand, and we do not expect this crisis to result in a backorder situation.
我們也已確認,位於聖地牙哥的關鍵供應商均已全面恢復運作。在危機期間,我們持續為患者提供不中斷的技術與客戶支援。雖然製造作業有數日受限,但我們目前擁有足夠的感測器庫存以滿足患者需求,且我們不預期此次危機會導致缺貨待補(backorder)的情況。
We are extremely pleased with the results of our first full quarter launch of the Seven. We believe the Seven is proving to be a better performing second generation product with noticeable performance benefits and greater ease of use for our patients. After more than a decade of no meaningful improvement in glucose control, using existing technologies, CGM is the first monitoring technology to show such significant gains in glucose control. We believe the Seven is creating the positive experiences for patients and healthcare professionals that we need to build this emerging category. Almost daily I hear reports of patients achieving their best ever glucose control without increasing their exposure to hypoglycemia.
我們對 Seven 上市後第一個完整季度的成果感到非常滿意。我們相信 Seven 正證明其為表現更佳的第二代產品,為患者帶來明顯的效能優勢與更高的易用性。在既有技術下,血糖控制已超過十年未見有意義的改善,而連續血糖監測(CGM)是第一項監測技術,能展現如此顯著的血糖控制提升。我們相信 Seven 正為患者與醫療專業人員創造我們建立此新興類別所需的正向體驗。幾乎每天我都聽到患者回報,在不增加低血糖暴露風險的情況下,達成他們有史以來最佳的血糖控制。
CGM is not just about insulin and insulin dosing. With CGM patients are able to observe in real-time the immediate impact of other activities affecting their glucose control, such as meals, exercise, and stress, and they are able to make appropriate timely behavioral modification. This continues to underscore why there is so much excitement and hope about CGM and why we continue to believe that continuous glucose monitoring will play a significant role in the future of diabetes management.
CGM 不僅僅關乎胰島素與胰島素劑量。透過 CGM,患者能夠即時觀察其他會影響其血糖控制之活動所帶來的立即影響,例如飲食、運動與壓力,並能及時做出適當的行為調整。這也持續凸顯為何市場對 CGM 充滿如此多的興奮與期待,以及為何我們仍然相信連續血糖監測將在未來的糖尿病管理中扮演重要角色。
I'd like to highlight just some key performance metrics for the third quarter. As Jess mentioned, revenue grew 41% sequentially from Q2 to Q3, and adding nearly 700 new customers in the third quarter, we saw a significant increase in the number of new patients added in our key accounts, suggesting that our targeted sales focus is gaining traction within these large diabetes centers. In addition, we successfully upgraded approximately 750 of our existing customers from the STS three-day to the Seven and we expect to continue to upgrade STS three-day customers during Q4. Most encouraging for the long-term viability of the business was a 30%, 36% increase in sensor revenues, quarter to quarter and a 75% increase compared to the third quarter of 2006.
我想強調第三季的一些關鍵績效指標。如 Jess 所提到,營收自第二季到第三季按季成長 41%;此外,第三季新增近 700 名新客戶,我們也看到在關鍵客戶中新增病患數顯著增加,顯示我們鎖定式的銷售聚焦正在這些大型糖尿病中心逐步奏效。另外,我們成功將約 750 名既有客戶從 STS 三日版升級至 Seven,並預期在第四季將持續推動 STS 三日版客戶升級。對於業務長期可行性最令人鼓舞的是,感測器營收按季增加 30% 至 36%,且相較於 2006 年第三季成長 75%。
Contrary to rumors, we did not experience an increase in out-of-box sensor failures during Q3. Product performance and quality as measured by complaint rate data continues to be extremely positive and at the same time manufacturing volumes continue to increase. For the balance of 2007 we will continue to focus our selling efforts on the largest diabetes centers in the U.S. Our targeted efforts in these key centers during the third quarter provided us the opportunity tor revisit the benefits of continuous glucose monitoring with patients and healthcare professionals who might have had an unfavorable initial experience with our STS three-day.
與傳聞相反,我們在第三季並未經歷開箱即故障(out-of-box)的感測器失效率上升。以客訴率數據衡量的產品表現與品質仍然極為正向,同時製造產量也持續提升。2007 年剩餘期間,我們將持續把銷售資源聚焦於美國最大的糖尿病中心。我們在第三季於這些關鍵中心的鎖定式努力,讓我們有機會與可能對我們 STS 三日版有不佳初期體驗的患者與醫療專業人員,再次溝通連續血糖監測的效益。
Our experience with the launch of the Seven during the third quarter has, in fact, revealed that the performance issues we experienced with the STS three-day may have disappointed patients and prescribers more than we initially believed. We believe that this has had a lingering affect, resulting in slower new patient and accounts conversion as we work to regain patients and physician confidence in the Seven. Nonetheless, we continue to see increasing excitement and clinical interest in the category of continuous glucose monitoring, whether it be at the scientific medical meetings or in daily interactions with physicians, educators, and patients.
事實上,我們在第三季推出 Seven 的經驗顯示,我們在 STS 三日版所遭遇的效能問題,可能讓患者與開立處方的醫師感到失望的程度,超過我們最初的預期。我們認為這造成了持續性的影響,使得在我們努力重新建立患者與醫師對 Seven 的信心之際,新患者與新帳戶的轉換速度較慢。儘管如此,無論是在科學醫學會議上,或是在與醫師、衛教師與患者的日常互動中,我們仍持續看到對連續血糖監測這一類別的興奮度與臨床興趣不斷提升。
CGM was a central focus at the American Diabetes Association Annual Meeting this summer, and was a key topic of discussion at the Diabetes Technology Society Meeting this past weekend. While we believe we've made significant progress raising the awareness of CGM and DexCom among physicians and clinical educators we have a long way to go to achieve the paradigm shift from a single point finger stick to CGM.
今年夏天的美國糖尿病協會(American Diabetes Association)年會以 CGM 為核心焦點,而 CGM 也是上週末糖尿病科技學會(Diabetes Technology Society)會議的主要討論議題。雖然我們相信在提升醫師與臨床衛教師對 CGM 與 DexCom 的認知方面已取得顯著進展,但要實現從單點指尖採血到 CGM 的典範轉移,我們仍有很長的路要走。
With our leadership role in the category we will continue to invest in activities to gain acceptance of CGM as the best standard of care for diabetes management. Looking forward, we will continue to focus on well proven tactics for category growth, including raising the awareness of DexCom among healthcare providers to increase clinical adoption and utilization of continuous glucose monitoring. Over time we must establish CGM as the best standard of care for diabetes management. Second, we must maintain our core focus on technology and product improvement. We've succeeded in bringing the best CGM technology to the market over the past two years, and believe we will continue to be the technology leader. Third, we must continue to push to achieve broad reimbursement for our patients.
憑藉我們在此類別的領導地位,我們將持續投資相關活動,以促使 CGM 被接受為糖尿病管理的最佳照護標準。展望未來,我們將持續聚焦於已被證實有效的類別成長策略,包括提升醫療照護提供者對 DexCom 的認知,以增加連續血糖監測的臨床採用與使用率。隨著時間推進,我們必須將 CGM 建立為糖尿病管理的最佳照護標準。第二,我們必須維持對技術與產品改良的核心聚焦。過去兩年我們已成功將最佳的 CGM 技術推向市場,並相信我們將持續成為技術領導者。第三,我們必須持續推動,為患者爭取更廣泛的給付(reimbursement)。
Moving to R&D, we believe that the continual introduction of next generation products with improved performance and patient convenience are key to the development and the growth of the CGM category. As we mentioned previously, during the second quarter of 2007 we filed a PMA supplement with the FDA to add additional functionality to the Seven to enable patients to calibrate the system using any brand of blood glucose meter. Although we cannot predict the ultimate decision or timing for a decision by the FDA, it would seem we are on track for a decision by the end of the year. We are currently in the final stages of our pivotal trial for our third generation STS, and we expect to file a PMA supplement with the FDA by the end of the year as we have committed previously.
談到研發(R&D),我們相信持續推出具備更佳效能與更高患者便利性的次世代產品,是 CGM 類別發展與成長的關鍵。如先前所述,我們在 2007 年第二季向 FDA 提交了 PMA 補充申請(PMA supplement),以為 Seven 增加額外功能,使患者可使用任何品牌的血糖機來校正系統。雖然我們無法預測 FDA 最終決定或決定時點,但看起來我們有望在年底前獲得決定。我們目前正處於第三代 STS 關鍵性試驗(pivotal trial)的最後階段,並預期將如先前承諾於年底前向 FDA 提交 PMA 補充申請。
We are also pleased to report that just last week we received approval from the Food & Drug Administration to transition our manufacturing operations to our expanded facility near our Corporate Headquarters. We are in the process of completing the build out of that facility and expect to consolidate our operations into that facility during the first quarter 2008. It is important to note that this approval was granted in large part based on our post-approval PMA and QSR audit conducted by the FDA in January 2007, continuing to demonstrate the outstanding relationship we have with the FDA, enabling us to bring forward new products we hope will improve the lives of people with diabetes. Even without significant optimization efforts our current estimates suggest that we should be able to produce approximately 1 million sensors annually in this new facility.
我們也很高興報告,就在上週我們獲得美國食品藥物管理局(Food & Drug Administration)的核准,得以將製造作業轉移至公司總部附近擴建後的廠房。我們正進行該設施的建置收尾,並預期於 2008 年第一季將營運整併至該設施。重要的是,此項核准在很大程度上是基於 FDA 於 2007 年 1 月進行的核准後 PMA 與 QSR 稽核,持續展現我們與 FDA 之間良好的合作關係,使我們能推出我們希望可改善糖尿病患者生活的新產品。即使不進行大幅度的最佳化,我們目前的估算顯示,在此新設施中我們每年應可生產約 100 萬個感測器。
Finally, we continue to pursue a [CEMR] for the Seven, and to that end we are currently working with a notified body in Europe to review our quality of system and to assist us in obtaining a CEMR. We have also identified clinical trial sites in France and the Netherlands and are currently working with several principal investigators to develop an appropriate protocol to begin trials in Europe in '08.
最後,我們仍持續為 Seven 取得 [CEMR] 而努力;為此,我們目前正與歐洲的公告機構(notified body)合作,審查我們的品質系統並協助我們取得 CEMR。我們也已在法國與荷蘭確認臨床試驗據點,並正與數位主要研究者合作制定適當的試驗方案,以於 08 年在歐洲啟動試驗。
Reimbursement, we continue to receive unsolicited reports from patients and physicians of favorable coverage decisions, and our own reimbursement organization is working to build upon those experiences to create wider reimbursement going forward, especially with private payers. Although anecdotal because the data is solely based on patient reports, we are seeing an increase in the number of patients who are receiving coverage for CGM. We continue to educate the private payer community on the role of CGM in assisting patients to better manage their glucose excursions, both hypoglycemia as well as hyperglycemia.
在給付方面,我們持續收到患者與醫師主動回報的有利承保決定,而我們自身的給付團隊也正在這些經驗基礎上,推動未來更廣泛的給付,尤其是針對民間保險支付方(private payers)。雖然這些屬於軼聞性資料,因為數據完全來自患者回報,但我們看到獲得 CGM 承保的患者人數正在增加。我們也持續向民間支付方社群宣導 CGM 在協助患者更好管理血糖波動(glucose excursions)方面的角色,包括低血糖與高血糖。
We expect [HIPICS Codes] covering the three components of our Seven System to be published in the Federal Register any day now, and these Codes would become effective on January 1st, 2008.
我們預期涵蓋 Seven 系統三個組件的 [HIPICS Codes] 將在近日於《聯邦公報》(Federal Register)公布,而這些代碼將於 2008 年 1 月 1 日生效。
The JDRF sponsored randomized reimbursement trial is expected to be fully enrolled by the end of the year, and we continue to participate actively. We continue to see reimbursement as one of the key challenges to achieving widespread adoption of CGM and reiterate that the reimbursement process takes time, patience, and perseverance. We are making progress, but it is still too early to predict when broad coverage will generally be available.
由 JDRF 贊助的隨機給付試驗(randomized reimbursement trial)預期將在年底前完成全數收案(fully enrolled),我們也持續積極參與。我們仍將給付視為實現 CGM 廣泛採用的關鍵挑戰之一,並重申給付流程需要時間、耐心與毅力。我們正在取得進展,但目前仍過早,無法預測何時能普遍取得廣泛承保。
We also continue to make good progress in the development of a system to address glycemic control in the ICU market. As an increased number of hospitals implement tight glycemic control protocols to reduce mortality and morbidity in their post surgical patients we recognize the need to increase our efforts in this key area for continuous glucose monitoring. Although it is still too early to predict a commercialization timeline we are working to define the best development and regulatory path for the product.
我們在開發用於解決加護病房(ICU)市場血糖控制的系統方面也持續取得良好進展。隨著越來越多醫院為降低術後患者的死亡率與罹病率而導入嚴格血糖控制(tight glycemic control)流程,我們認知到必須在連續血糖監測的這一關鍵領域加大投入。雖然目前仍過早預測商業化時程,但我們正致力於界定該產品最佳的開發與法規路徑。
We continue to have multiple discussions with potential partners and continue to believe in open architecture, whereby our sensor system is adaptable to multiple insulin delivery models, represents the best interests of patients and DexCom. Aside from insulin delivery we are learning a great deal about the potential for CGM to be used together with other diabetes drugs and devices to improve the convenience and effectiveness of diabetes management. We would expect to more aggressively pursue partnerships that will provide for mutually beneficial integration in the coming quarters.
我們持續與多家潛在合作夥伴進行討論,並持續相信開放式架構(open architecture)最符合患者與 DexCom 的利益;在此架構下,我們的感測器系統可適配多種胰島素輸送模式。除胰島素輸送之外,我們也正深入了解 CGM 與其他糖尿病藥物與裝置搭配使用、以提升糖尿病管理便利性與有效性的潛力。我們預期在未來幾季將更積極推動能帶來互利整合的合作夥伴關係。
With that, I'm going to turn it over to Steve Pacelli to update you on the Abbott litigation. Steve?
接下來,我要把時間交給 Steve Pacelli,向各位更新 Abbott 訴訟的最新進展。Steve?
Steve Pacelli - SVP Corporate Affairs
Steve Pacelli - SVP Corporate Affairs
Thanks, Terry.
謝謝你,Terry。
You'll recall that back in September of 2006 the Delaware Court granted our motion to stay the original case and disallowed Abbott's attempt to amend the original complaint to add three additional patents. Abbott subsequently filed a separate action on those three patents. On September 30th, 2007 the Court granted our motion to consolidate the cases and stay the entirety of the litigation pending conclusion of the reexamination proceeding with the PTO.
各位應該記得,早在 2006 年 9 月,德拉瓦州法院准許我們提出的暫緩原始案件之動議,並且不允許 Abbott 試圖修正原始起訴狀以新增三項額外專利。其後 Abbott 就這三項專利另行提起獨立訴訟。2007 年 9 月 30 日,法院准許我們提出的合併案件之動議,並在專利商標局(PTO)之再審查程序結束前,暫緩整體訴訟程序。
We believe this decision will suspend the litigation activity throughout 2008, however, we will continue to aggressively pursue reexamination of the Abbott patent cited against us. For traditional detail regarding the status of the reexamination proceedings, please take a look at our 10-Q filed today with the SEC.
我們相信此一裁定將使 2008 年全年的訴訟活動暫停;然而,我們仍將持續積極推動對 Abbott 用以對抗我們之專利的再審查。若要了解再審查程序狀態的傳統細節,請參閱我們今日向美國證券交易委員會(SEC)提交的 10-Q。
Terry?
Terry?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Thanks, Steve.
謝謝你,Steve。
In conclusion, as we complete the first full quarter launch of the Seven we believe as much as ever that continuous glucose monitoring will play an important role in diabetes management. Our daily experiences continue to reinforce that patients and healthcare professionals who make a commitment to using the product for a period of time, irrespective of first generation performance issues are obtaining their best levels of glucose controls ever. We continue to believe DexCom will be a growing and profitable business for the future.
總結來說,隨著我們完成 Seven 上市後的第一個完整季度,我們比以往任何時候都更相信連續血糖監測將在糖尿病管理中扮演重要角色。我們的日常經驗持續印證:無論第一代產品的效能問題為何,只要病患與醫療專業人員承諾在一段時間內使用本產品,就能獲得其有史以來最佳的血糖控制水準。我們仍然相信 DexCom 未來將是一項成長且獲利的事業。
I'll now take questions.
我現在開始回答問題。
Operator
Operator
(OPERATOR INSTRUCTIONS.)
(接線員指示。)
And we'll take our first question from Tom Gunderson with Piper Jaffray.
我們的第一個問題來自 Piper Jaffray 的 Tom Gunderson。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Hi, good afternoon. Terry, let me see if I've got this right, revenues are up and costs are down?
嗨,午安。Terry,讓我確認一下我是否理解正確:營收上升、成本下降?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Yes.
是的。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Okay. The -- you -- it was a good summary, and so I just have a couple of follow-ups on some of the comments you made. First off, can you remind me on the ICU project where we are with a -- from a design standpoint? Do you have a proof of principle design, CGM, that works within the hospital noise?
好的。你——你——剛才總結得很好,所以我有幾個針對你所提到的一些評論的追問。首先,能否提醒我 ICU 專案在設計面目前進展到哪裡?你們是否已有一個可行性驗證(proof of principle)的 CGM 設計,能在醫院的雜訊環境中運作?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Yes, Tom, that's a great question. We have designed this particular sensor to be an indwelling IV sensor so it's in the blood, and we have completed a number of feasibility trials, now slightly less than 100 patients through the clinic setting, and are continuing to refine that particular product with the hopes of being in a pivotal trial sometime next year.
是的,Tom,這是個很好的問題。我們將這款特定感測器設計為留置式 IV 感測器,因此它是在血液中。我們已完成多項可行性試驗,目前在臨床環境中累計受試病患略少於 100 位,並持續精進該產品,希望能在明年某個時間點進入關鍵性試驗(pivotal trial)。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Okay. Thanks. And then the other is on manufacturing, what -- what's the plan on the switchover? Do you build-up inventory ahead of time, do you run parallel for awhile, how do you actually make the switch?
好的,謝謝。另一個問題是製造方面,切換的計畫是什麼?你們會先建立庫存嗎?會並行運作一段時間嗎?實際上要如何完成切換?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Yes, and typically in these types of situations we will run parallel and bring one line up at a time over at the new facility while we continue to run our existing line here at the Overland address, and then once we've qualified it up, sequenced the new facility, then we'll bring the line back over. But it will be sequentially.
是的,通常在這類情況下,我們會採取並行運作:在新廠區一次啟用一條產線,同時我們仍在 Overland 這個地址維持現有產線運作;等新產線完成資格認證、並將新廠區的流程排程就緒後,再把產線移轉過去。但會是依序進行。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Okay. Thanks. And then, last quick question, how is the CFO search going?
好的,謝謝。最後一個快問:CFO 的徵才進度如何?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Well, right now, we -- we're pretty happy with the situation that we've got and, you know, I've got a lot of recommendations but I'm particularly focused right now on growing sales.
嗯,目前我們——我們對現況相當滿意,而且你知道,我收到很多推薦,但我現在特別專注在推動銷售成長。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Got it. Thank you.
了解,謝謝你。
Operator
Operator
And our next question comes from Ben Andrew with William Blair.
下一個問題來自 William Blair 的 Ben Andrew。
Ben Andrew - Analyst
Ben Andrew - Analyst
Good afternoon, Terry. Can you hear me?
午安,Terry。你聽得到我嗎?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Yes, Ben, I can hear you.
是的,Ben,我聽得到。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. Just a couple things. Can you talk about reorder rates for the new patients on the Seven, as well as if you've seen any patterns for reorder rates on patients that switched from the Three to the Seven in the last few months?
好的。幾件事想請教。你能談談 Seven 新病患的再訂購率(reorder rates)嗎?以及過去幾個月從 Three 轉換到 Seven 的病患,在再訂購率上是否看到任何模式?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
You know, I -- we'll probably -- we'll be able to comment on that after the next quarter. The problem right now is we're trying to get our arms around that. As you well know, we don't have a hard shut-off on the sensor, so -- and if you believe the blogs patients are using them right now somewhere between on average seven to ten days, but that is a metric that I expect to be able to disclose on a continuing basis, but it's just too early. We just now finished one quarter, so we don't have good optics.
你知道,我——我們可能——要到下一季之後才比較能評論。現在的問題是我們還在釐清這件事。如你所知,我們的感測器沒有硬性關閉(hard shut-off),所以——如果你相信部落格上的說法,病患目前平均使用天數大約在 7 到 10 天之間;但這是一個我預期能持續揭露的指標,只是現在還太早。我們才剛完成一個季度,所以還沒有很好的能見度。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. Any anecdotal comments there in terms of generally positive reorder rates versus what maybe we've seen historically?
好的。就軼聞(anecdotal)而言,你能否評論一下:整體再訂購率是否普遍偏正向,相較於我們過去可能看到的情況?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Yes. I'm very happy from what we're seeing, and we just want to be sure that we validate what we're seeing with hard data rather than some of the subjective observations that we're looking at now.
可以。就我們目前看到的情況,我非常滿意;我們只是想確保用硬數據來驗證我們所看到的,而不是僅依賴目前這些主觀觀察。
Ben Andrew - Analyst
Ben Andrew - Analyst
Sure. Okay. And then switching over to the European opportunity, do you have a timeframe in mind for [CE Mark], and how would you roll it out? I assume with distributors? And then how do you quantify that as a market opportunity for DexCom?
了解。好的。接著談歐洲機會,你們對於取得 [CE Mark] 是否有時間表?以及你們會如何推廣?我猜是透過經銷商?另外,你們如何量化這對 DexCom 的市場機會?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
The CE Mark, you know, generally once you go through the ISO certification, which we expect to receive sometime in the early part of '08, then you file for CE Mark, and that generally takes around 90 days but, that said, that just allows you to introduce the product into the sector, it does not necessarily generate any revenue for you. You have to go back in and seek reimbursement from each country. That's why we have targeted both the Netherlands and France, with some of my old friends there that are the luminaries in the field, and both of those countries have good reimbursement in diabetes technology. So we would look to initialize the relationship with them, complete the clinical trials, apply for reimbursement, and then in the meantime concurrently begin looking at a distribution partner in that sector.
關於 CE Mark,你知道,一般而言,一旦完成 ISO 認證——我們預期在 2008 年初的某個時間點取得——接著就會申請 CE Mark,而通常大約需要 90 天。不過話說回來,那只是讓你能把產品導入該市場領域,並不必然為你帶來任何營收。你必須回頭向各個國家逐一爭取給付(reimbursement)。這也是為什麼我們鎖定荷蘭與法國,當地有一些我以前的老朋友,是這個領域的權威人物,而這兩個國家在糖尿病科技方面的給付制度也不錯。因此我們會先與他們建立合作關係、完成臨床試驗、申請給付,同時並行開始在該領域尋找通路合作夥伴。
Ben Andrew - Analyst
Ben Andrew - Analyst
OK. Great. Thank you, Terry.
好的,很棒。謝謝你,Terry。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
You bet.
不客氣。
Operator
Operator
We'll move next to William Plovanic with Canaccord Adams.
接下來是 Canaccord Adams 的 William Plovanic。
William Plovanic - Analyst
William Plovanic - Analyst
Great. Thank you. Can you hear me?
很好,謝謝。你聽得到我嗎?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Bill, we can hear you great.
Bill,我們聽得很清楚。
William Plovanic - Analyst
William Plovanic - Analyst
Fantastic! Just a couple of questions here. In terms of the upgrades, we have 750, that's the cumulative number thus far; correct?
太好了!我這裡有幾個問題。關於升級(upgrades),我們看到 750,這是截至目前的累計數量;對嗎?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
No, that was the number in the quarter.
不是,那是本季度的數量。
William Plovanic - Analyst
William Plovanic - Analyst
So roughly what's the cumulative on the upgrade?
那升級的累計大約是多少?
Jess Roper - Interim CFO
Jess Roper - Interim CFO
We started the upgrade program in late Q2, and we did not deliver any units as of that time. We did upgrade customers during Q3, so that 700 and roughly 50, you can use as the cumulative to date upgrade number.
我們在第二季末啟動升級計畫,當時尚未交付任何機台。我們在第三季為客戶進行升級,所以那 700 加上大約 50,你可以把它視為截至目前的累計升級數量。
William Plovanic - Analyst
William Plovanic - Analyst
Okay. Great. And then what's, you know, what's your average cost that you're getting on these upgrades? I mean your average ASP on the upgrades?
好的,很好。那麼,這些升級的平均成本——也就是你們在升級上的平均售價(ASP)是多少?
Jess Roper - Interim CFO
Jess Roper - Interim CFO
We've disclosed it before, and that's $150 per upgrade.
我們之前已揭露過,是每次升級 150 美元。
William Plovanic - Analyst
William Plovanic - Analyst
Okay. And then, sorry, I'm just trying to run through some of the numbers here. I mean by my estimates you did about $700,000 in sensor revenue in the quarter; is that about right?
好的。然後,不好意思,我只是想把一些數字算清楚。以我的估算,你們本季度感測器營收大約是 70 萬美元;大概對嗎?
Jess Roper - Interim CFO
Jess Roper - Interim CFO
We have not announced before or disclosed our sensor revenues.
我們之前沒有公布或揭露過感測器營收。
William Plovanic - Analyst
William Plovanic - Analyst
Okay. And then in terms of U.S. distribution any -- any changes in the overall makeup of that channel at this point in terms of you had about 25 direct and about 20 clinical diabetes educators? Any changes or are you just sticking with what you have for the near term?
好的。那在美國通路方面,目前整體通路組成有——有任何變化嗎?就你們大約有 25 位直銷人員以及約 20 位臨床糖尿病衛教師而言?有任何調整,還是短期內就維持現狀?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Yes, I'm very comfortable with the size of that sales force right now and the combination between clinical education specialists and the traditional sales force. I think through the remainder of '07, as we mentioned, we're going to stick to the plan. It's working well.
是的,我目前對那支銷售團隊的規模,以及臨床教育專員與傳統銷售團隊之間的組合,都非常滿意。我認為在 07 年剩餘期間,如同我們提到的,我們會按計畫行事。這個做法運作得很好。
William Plovanic - Analyst
William Plovanic - Analyst
Uh-huh.
嗯哼。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
We're seeing a greater uptake in each of the locations that we're spending more time with, and so we're very happy with the process. We'll look at next year and the potential for expansion but right now I'm, at this point and for the remainder of '07 we're sized appropriately.
我們看到在每一個我們投入更多時間的據點,採用率都有更高的提升,因此我們對這個流程非常滿意。我們會評估明年以及擴張的可能性,但就目前而言,在此時點以及 07 年剩餘期間,我們的規模配置是恰當的。
William Plovanic - Analyst
William Plovanic - Analyst
But there hasn't been in those absolute numbers, there hasn't been a lot of changes either; correct?
但在那些絕對數字上,其實也沒有太多變化;對嗎?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
No, we've seen, actually other than when I first arrived here, a few months ago, we had some involuntary resignation. We replaced those people with some more senior people, but we've been stable. And then looking at where we're at now and their numbers I'm quite pleased with their performance.
沒有。事實上,除了我幾個月前剛到這裡時,我們有一些非自願離職之外,我們一直很穩定。我們用一些資深的人員替補了那些職缺;而且就我們現在的位置與他們的數字來看,我對他們的表現相當滿意。
William Plovanic - Analyst
William Plovanic - Analyst
Okay. And then, lastly, you talked about a next generation product in the third gen. I mean as you move forward in generations can we look for, you know, a closer average deviation from your comparable group? Is that kind of the goal on the next generation, or is it more user friendliness? I just wonder if you could give us some color on that?
好的。最後,你提到第三代的下一代產品。我的意思是,當你往後推進到不同世代時,我們是否可以期待相較於同類可比群組,你們的平均偏差會更接近?這是否是下一代的目標,或是更偏向提升易用性?想請你多補充一些看法?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Well, the -- are you talking about accuracy?
嗯——你是在談準確度嗎?
William Plovanic - Analyst
William Plovanic - Analyst
Yes.
是的。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Yes, I mean the goal, obviously, is to reduce the amount of deviation as we compare to finger stick measurements. And, obviously, we, you know, ultimately in order to get replacement claim we have to achieve that, so that's always the goal. That's the gold standard that we move to. But, obviously, you have to keep making technology, improve it, not only from the sensor standpoint, membrane technology, there's a lot of different issues that surround that particular issue. But, that said, also on the software side we'll continue to make improvements in the software and download capabilities of the information.
是的,我的意思是,目標很明確,就是在與指尖採血測量相比時,降低偏差幅度。而且很顯然,最終要取得替代性(replacement)主張,我們必須達成這點,所以這一直都是目標。這是我們要達到的黃金標準。但當然,你必須持續推進技術、加以改良,不僅是感測器端、膜(membrane)技術,還有許多不同議題都會影響這個特定問題。不過除此之外,在軟體端我們也會持續改進軟體與資訊下載能力。
William Plovanic - Analyst
William Plovanic - Analyst
I guess, and what my question is everybody is kind of looking for that magic, okay, you're close enough, you're good enough, and that'll drive tremendous adoption. Is that a gen three product, is that a gen four, what is that in your opinion just kind of looking at all your changes in the technology come together?
我想,我的問題是:大家都在找那個「魔法時刻」——好,已經夠接近了、夠好了,然後就會帶動大幅採用。依你看,那會是第三代產品嗎?第四代嗎?就你對技術各項變更整合起來的觀察,你怎麼看?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Well, we're certainly, as I mentioned, we're almost through the pivotal trial on the gen three. We have not looked at that data to determine what [MARD] is yet. I would be able to give you more information after we've had a chance to look at that data, what we think is the -- well, we're certainly closer than the Seven but I don't know if we're there yet, and I won't be able to know that until after we look at that data.
嗯,我們確實如我提到的,第三代的關鍵性試驗(pivotal trial)已經快完成了。我們還沒有看過那些數據來判定 [MARD] 目前是多少。我會在我們有機會檢視那些數據之後,才能提供你更多資訊,說明我們認為——嗯,我們肯定比 Seven 更接近,但我不知道是否已經到位;在我們看完那些數據之前,我也無法知道。
William Plovanic - Analyst
William Plovanic - Analyst
And when will we see that data?
那我們什麼時候會看到那些數據?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Well, we will file it with the agency by the end of the year, but you would see it sometime in the '08 timeframe.
嗯,我們會在年底前向主管機關提交,但你大概會在 08 年的時間範圍內看到。
William Plovanic - Analyst
William Plovanic - Analyst
Great. Thanks a lot, Terry.
太好了。非常感謝你,Terry。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
You bet.
不客氣。
Operator
Operator
We'll move now to Mimi Pham of HSBC.
我們現在轉到 HSBC 的 Mimi Pham。
Mimi Pham - Analyst
Mimi Pham - Analyst
Hi, good afternoon. Terry, I know you don't give guidance, but based on what you're seeing so far in the Seven demand do you expect new patient adds in the fourth quarter to be stronger than what we've seen for this quarter?
嗨,午安。Terry,我知道你不提供財測指引,但就你目前看到的 Seven 需求而言,你是否預期第四季的新病患新增數會比我們這一季看到的更強?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Well, that's always the goal. I mean that's why we look at the sales force. With that said, I will remind everyone that my goal for the organization through the end of '07 is stay the course at the largest centers. We're seeing better up take at those centers, which means we're changing the prescribing habit of the key thought leaders there, as well as some of the other endocrinologists and healthcare educators that are at those locations. So I think from that standpoint we'll look to '08 as more of a patient add number.
嗯,那一直都是目標。我的意思是,這也是我們檢視銷售團隊的原因。話雖如此,我要提醒大家,我對組織在 07 年底前的目標,是在最大型的中心持續按既定方向前進。我們看到那些中心的採用率更好,這表示我們正在改變那裡關鍵意見領袖的處方習慣,以及在那些據點的其他一些內分泌科醫師與醫療照護教育人員的處方習慣。所以我認為從這個角度來看,我們會把 08 年視為更偏向病患新增數的年份。
Right now, what we have to do is to continue to stay with these sites so that they utilize the technology in an ever increasing area. And they really become the spokespersons for the category as they go out and communicate to others treating the disease, and that's the mentality that has to go on and continue.
目前我們必須做的是,持續深耕這些據點,讓他們在越來越廣的範圍內使用這項技術。並且當他們走出去與其他治療此疾病的人溝通時,真正成為這個類別的代言人;這樣的心態必須建立並持續下去。
Mimi Pham - Analyst
Mimi Pham - Analyst
Okay. Thank you. And then how big is your internal coverage support group, and is that something you plan to build out as you add more patients, or as you plan to add more patients?
好的,謝謝。那你們內部的保險給付(coverage)支援團隊有多大?隨著你們新增更多病患,或計畫新增更多病患時,這會是你們打算擴編的部分嗎?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Yes, we don't disclose -- and I assume you're talking about our customer service, technical services group?
是的,我們不揭露——我猜你指的是我們的客服、技術服務團隊?
Mimi Pham - Analyst
Mimi Pham - Analyst
That one, too, and then just also the group that helps patients, new patients get reimbursed and are trying to get reimbursement?
那個也算,另外還有協助病患、尤其是新病患取得給付、並嘗試爭取給付的那個團隊?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
They're in -- internally the back office support encompasses all of those areas, and we haven't disclosed those numbers. I'm always careful about that because, remember, I -- I've done this before, and that number got very large at another company, and I have to be careful that this model isn't the same model, but we'll continue to support them. And we also have an external group that calls on the payer system that is also assisting in a different way, but to drive coverage decisions at that which will then make it easier for patients to receive reimbursement.
他們——內部的後勤辦公室支援涵蓋了所有那些領域,而我們沒有揭露那些人數。我對這點一向很謹慎,因為請記得,我——我以前做過這件事,而在另一家公司那個數字曾經變得非常大;我必須小心不要讓這個模式變成同樣的模式,但我們會持續提供支援。我們也有一個外部團隊在拜訪付款方(payer)體系,以不同方式提供協助,推動其做出保險給付(coverage)決策,進而讓病患更容易獲得理賠/給付。
Mimi Pham - Analyst
Mimi Pham - Analyst
Okay. I didn't realize you had an external group also helping with coverage. And then, last, for -- you talked about multiple partner discussions, are any of these potential partners, will they distribute the Seven or is this more integrating their product, the product features?
好的。我之前不知道你們也有外部團隊在協助給付。最後,關於——你提到與多個夥伴的洽談,這些潛在夥伴是否會經銷 Seven?還是比較偏向把他們的產品、產品功能整合進來?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Right now, I mean I don't want to go to the details of the discussions other than to say our -- and our standard public statement has been that we will integrate. Obviously, as you think about that integration into a combination product, it would obviously involve some degree of distribution on the part of the partners.
目前,我不想深入討論細節;我只能說,我們——我們一貫對外的公開說法是我們會進行整合。當然,當你思考把它整合成一個組合式產品時,顯然也會涉及合作夥伴在某種程度上的通路/經銷。
Mimi Pham - Analyst
Mimi Pham - Analyst
Okay. Thank you very much.
好的。非常感謝。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Uh-huh.
嗯哼。
Operator
Operator
And we'll take our next question from Steve Ogilvie with ThinkEquity.
我們下一個問題來自 ThinkEquity 的 Steve Ogilvie。
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
Hi. Just wanted to ask what impact there will be on the cost of goods when you move into the new facility?
嗨。我想問的是,當你們搬進新廠房時,對銷貨成本會有什麼影響?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Well, obviously, we've got a greater cost, so from that standpoint, well, you know, that'll be applied on a per unit basis, but that's, you know, obviously, we believe still run rates are going to dictate getting to the gross margins that we've stated from a standpoint of this is a product, a sensor product is a product that should have gross margin north of 75%, so we're still negative margins for awhile until we can get our run rates appropriate.
嗯,很明顯我們的成本會更高,所以從那個角度來看,嗯,你知道,這會以每單位成本的方式反映;但你知道,很顯然,我們仍然相信,產能運轉率(run rates)將決定我們能否達到先前所說的毛利率。從產品角度來看,感測器產品應該要有 75% 以上的毛利率,所以在我們把運轉率拉到合適水準之前,毛利率還會負一段時間。
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
Okay. And then on reimbursement, so say finish and rolling by the end of this year, really the primary implant is a six-month follow-up, sometime midway through next year we'll have some data. Is this Company going to take any sort of active role in pursuing reimbursement and, if not, could you maybe walk us through what JDRF will do to get reimbursement?
好的。那在給付(reimbursement)方面,假設今年底完成並開始推進,主要的里程碑其實是六個月的追蹤,明年年中左右我們會有一些數據。公司是否會在爭取給付上扮演任何積極角色?如果不會,你能否帶我們了解 JDRF 會如何推動取得給付?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Sure. And let me first state, we have a field force of several individuals, headed up by an individual that ran reimbursement for me at my former company, so he's been down this pathway from going from zero reimbursement to today pumps out north of 95% reimbursement, so he knows the drill. He heads up a team that calls on the third-party payer system, as we speak, and they're making tremendous inroads into -- in getting that coverage decision. So that -- that's one aspect of it.
當然可以。我先說明,我們有一支由數位成員組成的外勤團隊,由一位曾在我前一家公司負責給付(reimbursement)的人帶領;他走過這條路,從零給付一路做到今天胰島素幫浦的給付率超過 95%,所以他很清楚流程。他帶領的團隊目前正在拜訪第三方付款方(third-party payer)體系,而且他們在取得給付決策方面已經取得非常大的進展。所以——這是其中一個面向。
The JDRF trial is a trial which is designed by investigators and JDRF specifically looking at reduction in [HBA1C] over a year period, s well as increasing time spent and target zone, decreasing time spent in hypoglycemia and hyperglycemia. The interim analysis at six months is something that JDRF will do, and I really have to refer you to [Eric Kowalski] at JDRF for any specificity with regards to the trial. We're contributing product as is the -- our competitors but we don't control the analysis or any of the publications associated with the information.
JDRF 試驗是一項由研究人員與 JDRF 共同設計的試驗,特別著眼於在一年期間內降低 [HBA1C],同時增加處於目標區間的時間、減少低血糖與高血糖的時間。六個月的期中分析將由 JDRF 進行,至於該試驗的任何具體細節,我確實必須請您洽詢 JDRF 的 [Eric Kowalski]。我們會提供產品,我們的競爭對手也會提供,但我們不控制分析,也不控制與該資訊相關的任何出版物。
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
Great. Thank you.
很好。謝謝。
Operator
Operator
And our last question comes from Alex Arrow of Lazard Capital Marketing.
我們的最後一個問題來自 Lazard Capital Marketing 的 Alex Arrow。
Alex Arrow - Analyst
Alex Arrow - Analyst
Thanks. Can you assume that the three-day sensor is going to be entirely retired as you roll out the Seven?
謝謝。你們在推出 Seven 的同時,是否可以假設三日感測器將會完全退役?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Well, we're in the process, globally encouraging patients to move up to the Seven. The goal is ultimately to retire the Three. I can't tell you when that's going to happen other than we'll continue to support it until we can switch patients over, but we're right now in the process of encouraging them to switch over.
嗯,我們正在全球範圍內鼓勵病患升級到 Seven。最終目標是讓 Three 退役。我無法告訴你何時會發生;除了我們會持續支援它,直到我們能把病患轉換過去。不過我們目前正處於鼓勵他們轉換的過程中。
Alex Arrow - Analyst
Alex Arrow - Analyst
Are you able or willing to tell us roughly what portion of sensors this revenue were Seven?
你們是否能或願意告訴我們,大約有多少比例的感測器營收來自 Seven?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
We haven't disclosed that yet, Alex.
Alex,我們尚未披露那個數字。
Alex Arrow - Analyst
Alex Arrow - Analyst
Okay. How about the -- I think I heard you say seven to ten days was what you were hearing back as generally how long patients are using the Seven System; is that correct? Because I remember the Three was used longer than the three, the Seven, are you hearing than it's being used longer than the seven?
好的。那關於——我想我聽到你說一般回饋是病患使用 Seven 系統大約七到十天;這樣說對嗎?因為我記得 Three 的使用時間會超過三天;那麼對 Seven,你們聽到的是使用時間也會超過七天嗎?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Yes, we're -- and we monitor the blogs, and I can tell you that on average we're seeing routine use north of seven days and somewhere between seven and ten days.
是的,我們——而且我們會監測部落格;我可以告訴你,平均而言我們看到的例行使用天數通常超過七天,大約介於七到十天之間。
Alex Arrow - Analyst
Alex Arrow - Analyst
Okay. And then, finally, if I could just ask about your latest thinking on non-Medicare third-party reimbursers, is there anything you can tell us about the major insurers that might be either a movement in the direction of reimbursement, you know, in advance of any JDRF data?
好的。最後,如果我可以問一下你們對非 Medicare 的第三方給付方最新的看法,你們是否能談談主要保險公司是否有任何朝向給付的動向——你知道,在任何 JDRF 數據出來之前?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Yes, I mean we're continuing to go up the hierarchy within the reimbursement group on the private payer basis. I would expect that, hopefully, even yet this year we will have at least a contract relationship with a major payer. That's not a coverage decision, it's just a contract agreement with them, which is the predecessor to a coverage decision. And that's the normal, typical way in which these products get adopted and reimbursed.
是的,我的意思是,我們持續在私人付費方的基礎上,往給付部門的更高層級推進。我希望,甚至在今年之內,我們至少能與一家主要付費方建立合約關係。那不是承保決定,只是與他們的合約協議,而這是承保決定之前的前置步驟。這也是這類產品被採用並獲得給付的正常、典型方式。
Alex Arrow - Analyst
Alex Arrow - Analyst
A contract relationship is not a promise to pay, it's just an application to -- on a case-by-case basis?
合約關係並不是付款承諾,只是——逐案申請嗎?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Well, it still goes case-by-case. It's not a coverage decision but it is an agreement that they recognize that a number of their covered lives who qualify, depending upon what the criteria is, and that's going to be, depending upon the payer that they will agree to cover that without having to go through a prior approval or having to go through the -- a denial and appeal process, and those are the early steps of adoption that new technology generally follows. And then at some subsequent period there will be a coverage decision that may be restrictive in terms of the criteria for acceptance but it is a broader based coverage decision.
嗯,仍然是逐案處理。這不是承保決定,但它是一項協議:他們承認其承保人群中有一定數量符合資格者——資格標準取決於他們的條件——而且依不同付費方而定,他們會同意在不需要事前核准、或不必經過——拒賠與申訴流程的情況下予以給付。這些是新技術一般遵循的早期採用步驟。之後在某個時間點會有承保決定;該決定在接受標準上可能較為嚴格,但它會是一個更廣泛的承保決定。
Alex Arrow - Analyst
Alex Arrow - Analyst
Okay. So but before December 31st you're saying you'll announce somebody with a contract relationship?
好的。所以你是說在 12 月 31 日之前,你們會宣布某家與你們有合約關係的付費方?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
No, I can't tell you that we will. I -- my comment was I am hopeful. Obviously, with our field team negotiating and with a number of large payers at the present time we feel that there may be an opportunity before the end of the year to have a contract in place.
不,我不能告訴你我們一定會。我——我的評論是我抱持希望。顯然,隨著我們的前線團隊正在談判,且目前與多家大型付費方接洽,我們覺得在年底前可能有機會把合約落實。
Alex Arrow - Analyst
Alex Arrow - Analyst
Okay. Thank you.
好的。謝謝。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Uh-huh.
嗯哼。
Operator
Operator
And we'll take a follow-up from William Plovanic with Canaccord Adams.
我們接著接受 Canaccord Adams 的 William Plovanic 的追問。
William Plovanic - Analyst
William Plovanic - Analyst
Great. Thanks. My two questions are this. So you've had about roughly 750 upgrades out of about 4,300 in the -- out in the market on the three-day. You know, how many of those 4,300 were active, so how many do you think cumulatively you'll end up upgrading to the seven-day? That's my first question.
很好,謝謝。我有兩個問題。第一,你們在市場上的三日系統大約有 4,300 台,其中大約有 750 台升級了。你知道,那 4,300 台裡有多少是活躍用戶?也就是說,你們認為累計最終會有多少升級到七日系統?這是我的第一個問題。
And the second question is in terms of the disposables you're getting a mix going in the quarter, kind of what was your ASP on the disposables? You know, are you sticking to and getting this, you know, $60 per sensor for the Seven?
第二個問題是,就耗材而言,你們在本季的組合有所變化;耗材的 ASP(平均銷售價格)大概是多少?你們是否仍維持並達成 Seven 每個感測器 60 美元的價格?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
The first question with regards to the three-day, I'm -- we haven't discussed that, so it's -- but I'd prefer not to address that. I can tell you on the ASP that we're getting, sticking to the $60 and we've seen no variation from that at this point. And I'm actually looking over at Jess just to verify, but we haven't had any -- we're not in a discount mode, we're selling them at full price.
第一個關於三日系統的問題,我——我們沒有討論過,所以——但我比較希望不回答。我可以告訴你,關於我們取得的 ASP,我們維持在 60 美元,而且到目前為止沒有看到任何變動。我其實也看向 Jess 只是要確認一下,但我們沒有——我們不在折扣模式,我們是以全價銷售。
William Plovanic - Analyst
William Plovanic - Analyst
Okay. And it looks like you're giving your base kits, you're getting a higher ASP for them, as well? Is that a fair statement?
好的。而且看起來你們的基本套件也取得了更高的 ASP?這樣說公平嗎?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
That's a fair statement.
這樣說很公平。
William Plovanic - Analyst
William Plovanic - Analyst
Okay. Great. Thanks a lot.
好的。很好。非常感謝。
Operator
Operator
And that concludes the Q&A session today. At this time, Mr. Gregg, I'd like to turn the conference back over to you for any additional or closing remarks.
以上為今天的問答環節。此時,Gregg 先生,我想把電話會議交回給您,請您做任何補充或結語。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Well, I just would like to thank everybody for the opportunity to review the quarter. Obviously, we're extremely pleased with the quarter performance. I've been onboard now 120 days, and I'm quite pleased to see the Company going in the direction that they are. I've been out in the field routinely, meeting with key luminaries that certainly I've had relationships with, and some of them are actually our best customers, as they also suffer from diabetes and have recognized the true benefit of better control. The future is very bright, and I look forward to chatting with you again to give you an update on the fourth quarter. Thank you.
嗯,我只是想感謝各位給我們機會回顧本季。顯然,我們對本季表現非常滿意。我加入公司至今 120 天,我很高興看到公司正朝著目前的方向前進。我也經常到第一線,與一些關鍵意見領袖會面;其中有些人我過去就有合作關係,而有些人其實也是我們最好的客戶,因為他們同樣罹患糖尿病,並已認知到更佳控制所帶來的真正效益。未來非常光明,我期待再次與各位交流,向各位更新第四季的情況。謝謝。
Operator
Operator
And, ladies and gentlemen, that does conclude today's conference. Thank you for your participation. You may now disconnect.
各位女士、先生,今天的電話會議到此結束。感謝各位的參與。您現在可以掛線。